NCT00703573

A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of 2 Doses of S-777469 (400 mg BID and 800 mg BID) in Patients With Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 209 (actual)
• Sponsor: Shionogi · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of 2 doses of S-777469 in patients with atopic dermatitis.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	S-777469 400 mg	S-777469 400 mg BID
DRUG	S-777469 800 mg	S-777469 800 mg BID
DRUG	Placebo	Placebo BID

Timeline

• Start date: 2008-05-01
• Primary completion: 2009-05-01
• Completion: 2009-12-01
• First posted: 2008-06-23
• Last updated: 2018-05-08

Locations

33 sites across 1 country: United States